CGRP antibodies: the Holy Grail for migraine prevention?

Affiliations

Comment

Julio Pascual. Lancet Neurol. 2015 Nov.

. 2015 Nov;14(11):1066-7.

doi: 10.1016/S1474-4422(15)00244-6. Epub 2015 Sep 30.

¹ University Hospital Marqués de Valdecilla and IDIVAL, 39011 Santander, Spain. Electronic address: juliopascual@telefonica.net.

No abstract available

Comment on

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD. Bigal ME, et al. Lancet Neurol. 2015 Nov;14(11):1091-100. doi: 10.1016/S1474-4422(15)00245-8. Epub 2015 Sep 30. Lancet Neurol. 2015. PMID: 26432181 Clinical Trial.
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB. Bigal ME, et al. Lancet Neurol. 2015 Nov;14(11):1081-90. doi: 10.1016/S1474-4422(15)00249-5. Epub 2015 Sep 30. Lancet Neurol. 2015. PMID: 26432182 Clinical Trial.